<?xml version="1.0" encoding="UTF-8"?>
<p>Results for each model and scenario were evaluated and compared for: new HIV infections, numbers of VMMC conducted, cost of VMMC and cost of ART, and the resulting number of VMMCs or cost per infection averted, relative to the counterfactual scenario without the VMMC program. We did this in turn for multiple timeframes, looking either historically (over 2009â€“2016) or into the future (projecting forward from 2017 through 2030). In the Results section, the presented ranges reflect differences in parameters and structure between the three models (Section D in 
 <xref ref-type="supplementary-material" rid="pone.0199453.s001">S1 File</xref>).
</p>
